Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • Bayer, Monsanto agbio/environmental news

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Monsanto Co. (NYSE:MON), St. Louis, Mo. Business: Agbio/Environmental Bayer will acquire Monsanto for $128 per share in cash. The companies said the deal values Monsantos …

    Published on 9/19/2016
  • Catalyst Biosciences hematology news

    Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Business: Hematology Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB …

    Published on 9/19/2016
  • Lundbeck neurology, generics news

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology, Generics The EU General Court upheld a decision from the European Commission to fine Lundbeck for anticompetitive activity related to Lundbecks …

    Published on 9/19/2016
  • Rigel autoimmune news

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Business: Autoimmune Rigel is reducing headcount by 46 (38%) to about 75 to focus on the launch of fostamatinib. The cuts will mostly come from the …

    Published on 9/19/2016
  • Amgen, Apotex hematology, biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Apotex Inc., Toronto, Ontario Business: Hematology, Biosimilars A federal judge in the U.S. District Court for the Southern District of Florida ruled that two biosimilars …

    Published on 9/12/2016
  • Moderna Therapeutics, U.S. Department of Health and Human Services infectious news

    Moderna Therapeutics Inc., Cambridge, Mass. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) granted Moderna a …

    Published on 9/12/2016
  • Takeda, U.S. Department of Health and Human Services infectious news

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded …

    Published on 9/12/2016
  • Cerulean cancer news

    Cerulean Pharma Inc. (NASDAQ:CERU), Waltham, Mass. Business: Cancer Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint in a Phase II trial to treat metastatic renal…

    Published on 9/5/2016
  • Chembio, U.S. Department of Health and Human Services diagnostic news

    Chembio Diagnostics Inc. (NASDAQ:CEMI), Medford, N.Y. U.S. Department of Health and Human Services, Washington, D.C. Business: Diagnostic HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded …

    Published on 9/5/2016
  • Mylan, Teva autoimmune news

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Autoimmune In inter partes review (IPR) proceedings, the U.S. Patent Trial and Appeal Board …

    Published on 9/5/2016
  • Novartis gene/cell therapy, cancer news

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Gene/Cell therapy, Cancer Novartis is dissolving its Cell and Gene Therapies Unit and re-integrating the units activities into its larger organization. The …

    Published on 9/5/2016
  • OraSure, U.S. Department of Health and Human Services diagnostic news

    OraSure Technologies Inc. (NASDAQ:OSUR), Bethlehem, Pa. U.S. Department of Health and Human Services, Washington, D.C. Business: Diagnostic HHSs Biomedical Advanced Research and Development Authority (BARDA) awarded …

    Published on 9/5/2016
  • Santhera musculoskeletal news

    Santhera Pharmaceuticals Holding AG (SIX:SANN), Liestal, Switzerland Business: Musculoskeletal Santhera received a $246,000 grant from FDA under its Orphan Products Grants Program to support the ongoing open-label, dose…

    Published on 9/5/2016
  • Amgen pharmaceuticals news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Pharmaceuticals Amgen launched a commercial office in Hong Kong. The company said the office will enhance the exchange of scientific ideas, foster more research …

    Published on 8/22/2016
  • Chiasma endocrine/metabolic news

    Chiasma Inc. (NASDAQ:CHMA), Waltham, Mass. Business: Endocrine/Metabolic Chiasma will reduce headcount by about 44% to less than 25 in its second wave of reductions since FDA issued a complete response letter in April …

    Published on 8/22/2016
  • Emergent BioSolutions, Centers for Disease Control and Prevention infectious news

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. U.S. Centers for Disease Control and Prevention, Atlanta, Ga. Business: Infectious Emergent said the CDC exercised an option under a 2012 deal for Emergent to supply…

    Published on 8/22/2016
  • J&J autoimmune news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune A federal judge in the U.S. District Court for the District of Massachusetts ruled that Johnson & Johnsons U.S. Patent No. 6,284,471, which covers …

    Published on 8/22/2016
  • The Jackson Laboratory, NIH neurology news

    The Jackson Laboratory, Bar Harbor, Maine National Institutes of Health, Bethesda, Md. Business: Neurology The Jackson Laboratory received a five-year, $11.7 million grant from NIHs National Institute on Drug Abuse (…

    Published on 8/22/2016
  • AbbVie, Amgen autoimmune, biosimilars news

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Autoimmune, Biosimilars AbbVie filed suit in the U.S. District Court for the District of Delaware alleging that Amgens ABP…

    Published on 8/15/2016
  • Embera, NIH neurology news

    Embera NeuroTherapeutics Inc., Shreveport, La. National Institutes of Health, Bethesda, Md. Business: Neurology Embera received an $11.1 million, three-year grant from NIHs National Institute on Drug Abuse (NIDA) to …

    Published on 8/15/2016
  • Pernix Therapeutics neurology news

    Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), Morristown, N.J. Business: Neurology In July, Pernix restructured its sales organization and reduced overall headcount by 60 (about 23%). The cuts include 54 sales …

    Published on 8/15/2016
  • pSivida ophthalmic news

    pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Business: Ophthalmic In July, pSivida said it plans to consolidate all R&D to its facility in Watertown. Subject to an employee consultation process required by U.…

    Published on 8/15/2016
  • Tokai cancer news

    Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Business: Cancer Tokai will reduce headcount by about 15 (60%) to 10 after it discontinued in July the Phase III ARMOR3-SV trial of galeterone (TOK-001) to …

    Published on 8/15/2016
  • Aegerion endocrine/metabolic news

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), Cambridge, Mass. Business: Endocrine/Metabolic Aegerion will reduce headcount for the second time this year by about 13% and will evaluate options, including divestiture or …

    Published on 8/8/2016
  • Allergan, Teva generics news

    Allergan plc (NYSE:AGN), Dublin, Ireland Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Generics Teva completed its acquisition of Allergans global generic pharmaceuticals business for $…

    Published on 8/8/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993